Key Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of metastatic or locally advanced
             solid tumors for which no standard therapy exists or standard therapy has failed
             because of disease progression or unacceptable toxicities.

          -  Cohort 1 (colorectal cancer): a) CRC (including microsatellite instability-high
             [MSI-H] and microsatellite-stable [MSS]) regardless of RAS mutation. b) Disease
             progression within 3 months after last administration of approved standard therapies.
             c) Prior cytotoxic chemotherapy for metastatic disease include all the following
             agents: fluoropyrimidine, oxaliplatin, and irinotecan

          -  Adjuvant chemotherapy-based treatments count as prior therapy, as long as relapse had
             occurred within 6 months of completion of such therapies, prior anti-epidermal growth
             factor receptor (EGFR) therapy (cetuximab, panitumumab), anti-angiogenic therapy
             (bevacizumab, aflibercept, ramucirumab), regorafenib, and TAS-102 are allowed. d) No
             more than 5 prior therapies for metastatic disease. For participants who had disease
             recurrence within 6 months of completing adjuvant chemotherapy, the adjuvant regimen
             can be considered as 1 chemotherapy regimen for metastatic disease

          -  Cohort 2 (NSCLC): a) NSCLC without known EGFR, anaplastic lymphoma kinase (ALK), and
             ROS1 genomic tumor aberrations. b) No standard therapy exists or standard therapy has
             failed. c) No more than 3 prior therapies for metastatic disease

        Key Exclusion Criteria:

          -  Primary central nervous system (CNS) tumor (Phase 1), CNS metastasis, and/or
             carcinomatous meningitis. Participants with prior brain metastases treated at least 4
             weeks before the first dose of EU101 that are clinically stable and do not require
             chronic corticosteroid treatment are allowed

          -  Received prior therapy with any anti-CD137 monoclonal antibody (mAb) or agent

          -  Major surgery requiring general anesthesia within 3 weeks before first dose of EU101
             or still recovering from prior surgery

          -  History of allogeneic tissue or organ transplant

          -  Human immunodeficiency virus (HIV) infection

          -  Active hepatitis B virus or hepatitis C virus infection

          -  Current or history of interstitial lung disease, anaphylaxis, uncontrolled asthma, or
             pneumonitis that has required systemic corticosteroids

        Other protocol defined Inclusion/Exclusion criteria may apply